ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2022

9:00AM-10:30AM: Abstract Number: 1657

Extreme Phenotype Approach Identifies Rare Variants in Systemic Sclerosis and Dermatomyositis Patients with Severe Calcinosis

Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

9:00AM-10:30AM: Abstract Number: 1659

FAM13A (Family with Sequence Similarity 13 Member A) Polymorphism Is Associated with Presence of a Radiographic Usual Interstitial Pneumonia Pattern in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

9:00AM-10:30AM: Abstract Number: 1649

Five-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management

Abstracts: RA – Diagnosis, Manifestations, and Outcomes II: Cardiovascular and Other Comorbidities

9:00AM-10:30AM: Abstract Number: 1633

Genetic Risk, Adherence to a Healthy Lifestyle, and Incident Gout in US Women and Men

Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

9:00AM-10:30AM: Abstract Number: 1654

Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares

Abstracts: SLE – Treatment

9:00AM-10:30AM: Abstract Number: L01

Impact of Glucocorticoid Dosing and Anti-Osteoporotic Treatment on Bone Health in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Longitudinal Cohort Study

Late-Breaking Abstracts (L01–L06)

9:00AM-10:30AM: Abstract Number: 1647

Increased Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Matched Cohort Study with Cancer Registry Linkage

Abstracts: RA – Diagnosis, Manifestations, and Outcomes II: Cardiovascular and Other Comorbidities

9:00AM-10:30AM: Abstract Number: 1636

Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort

Abstracts: Epidemiology and Public Health I: Risk Factors and Outcomes

9:00AM-10:30AM: Abstract Number: 1652

Long-term Safety and Efficacy of Anifrolumab in Adult Patients with Systemic Lupus Erythematosus: A Multicenter, Randomized, Double-blind, Placebo-controlled 3-year TULIP Extension Study

Abstracts: SLE – Treatment

9:00AM-10:30AM: Abstract Number: 1646

Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs Initiation in Patients with Rheumatoid Arthritis

Abstracts: RA – Diagnosis, Manifestations, and Outcomes II: Cardiovascular and Other Comorbidities

9:00AM-10:30AM: Abstract Number: 1642

Mast Cells May Explain Sex Differences in Osteoarthritis Pain

Abstracts: Osteoarthritis – Clinical

9:00AM-10:30AM: Abstract Number: 1662

Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern

Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

9:00AM-10:00AM: Abstract Number: 1632

Novel Autoantibodies Identify Sjögren’s Disease in Patients Lacking Serum IgG Specific for Ro/SS-A and La/SS-B

Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

9:00AM-10:30AM: Abstract Number: 1661

Osteoclastogenesis and Vascular Endothelial Growth Factor Blood Levels in Patients with Systemic Sclerosis with and Without Calcinosis Cutis

Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

9:00AM-10:00AM: Abstract Number: 1631

Phospholipase D 4 Is a Novel Surface Marker of a Distinctive B Cell Population Overlapping with Double Negative 2 B Cells

Abstracts: B Cell Biology and Targets in Autoimmune and Inflammatory Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].